Gastrointestinal Manifestations of Coronavirus Disease 2019 Across the United States: A Multicenter Cohort Study

Patel, Ankur; Sanders, Troy K; Prakash, Preeti; Law, Jade; Alvencar, Sujay; Choi, Alyssa Y.; Shah, Janaki; Patel, Kamal; Srivoleti, Padmavathi; Chauhan, Kirtan; Weissman, Simcha; Holzwanger, Erik; Dhingra, Rohit; Nguyen, Michelle C.; Kim, Daniel; Sidhu, Tahnee; Stallwood, Christopher; Dickstein, Aaron; Parekh, Nimisha K.; Altayar, Osama; Ciorba, Matthew A.; Yu, Jessica X.; Chen, Lea Ann; Tabibian, James H.; Limketkai, Berkeley N.

doi:10.1016/j.gastha.2022.07.002

Cited by 7 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, the data collection duration overlapped with the onset of the COVID-19 pandemic. COVID-19 can cause several non-specific symptoms, such as fever and abdominal pain, and could contribute to selection bias [ 27 ]. That illness has famously caused mild to moderate organ dysfunction and might result in abnormal laboratory values (i.e., WBC, AST) [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Developing a Simple Score for Diagnosis of Acute Cholecystitis at the Emergency Department

et al. 2022

View full text Add to dashboard Cite

We aim to develop a diagnostic score for acute cholecystitis that integrates symptoms, physical examinations, and laboratory data to help clinicians for timely detection and early treatment of this disease. We retrospectively collected data from our database from 2010 to 2020. Patients with acute abdominal pain who underwent an ultrasound or computed tomography (CT) scan at the emergency department (ED) were included. Cases were identified by pathological, CT, or ultrasound reports. Non-cases were those who did not fulfill any of these criteria. Multivariable regression analysis was conducted to identify predictors of acute cholecystitis. The model included 244 patients suspected of acute cholecystitis. Eighty-six patients (35.2%) were acute cholecystitis confirmed cases. Five final predictors remained within the reduced logistic model: age < 60, nausea and/or vomiting, right upper quadrant pain, positive Murphy’s sign, and AST ≥ two times upper limit of normal. A practical score diagnostic performance was AuROC 0.74 (95% CI, 0.67–0.81). Patients were categorized with a high probability of acute cholecystitis at score points of 9–12 with a positive likelihood ratio of 3.79 (95% CI, 1.68–8.94). ED Chole Score from these five predictors may aid in diagnosing acute cholecystitis at ED. Patients with an ED Chole Score >8 should be further investigated.

show abstract

Section: Discussionmentioning

confidence: 99%

Developing a Simple Score for Diagnosis of Acute Cholecystitis at the Emergency Department

et al. 2022

View full text Add to dashboard Cite

show abstract

“…On the other hands, GI symptoms was observed less frequent in a multicenter study from United States (18.9%) and among them diarrhea was the most common GI manifestation observed in 15.2% of the COVID-19 positive patients. 12 . This discrepancy in the published data has no proven reason and further researches are needed to make a firm conclusion.…”

Section: Introductionmentioning

confidence: 99%

Prevalence of Different Gastrointestinal Manifestations in Patients with Covid 19 Presenting to Gastroenterology OPD at Rawal Institute of Health Sciences, Islamabad

Abbasi,

Zameer,

Umar

et al. 2023

PJMHS

View full text Add to dashboard Cite

Objective: The objective behind this study was to determine the prevalence of different gastrointestinal manifestations in patients with COVID-19 presenting to gastroenterology OPD at Rawal Institute of health sciences, Islamabad Methods: this was a descriptive observational hospital-based study conducted through a convenient sampling technique. All the adult males and females diagnosed as COVID-19 for the first time were included in this study. Pregnant females, concomitant viral hepatitis, typhoid fever, known gastrointestinal disease, and those who did not consent to participate were excluded from this study. Proforma was used to collect the relevant data. Data regarding GI symptoms were collected and presented in the form of frequency and percentages. Results: Final analysis was performed on 193 COVID-19 positive patients. Diagnosed patients were mostly young with mean age was 39.42±18.29 years. More than 68% of the patients were males. Sixty-eight (35.23%) of the COVID-19 PCR positive patients presented with symptoms of gastrointestinal manifestations and the most common GI symptom was presence of Dysgeusia (52.94%, n = 36). Conclusions: Most of our study subjects belongs to young age group. The prevalence of GI manifestations are quite high as observed in our study and the most common GI symptoms was dysgeusia. Keywords: COVID-19 infection, gastrointestinal symptoms, clinical manifestation, Pakistan

show abstract

“…, sore throat, cough, dyspnea) being the most prevalent manifestation as a result of host seeding via angiotensin-converting enzyme 2 (ACE-2) receptors present primarily in type II alveolar cells of the lungs[ 4 , 5 ]. Although respiratory and non-specific symptoms such as fever, myalgia, and fatigue represented the most common presentations in patients with COVID-19 infection, gastrointestinal and hepatic symptoms have also been observed[ 6 , 7 ]. Infected individuals reported nausea, vomiting, and abdominal discomfort[ 6 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

“…Although respiratory and non-specific symptoms such as fever, myalgia, and fatigue represented the most common presentations in patients with COVID-19 infection, gastrointestinal and hepatic symptoms have also been observed[ 6 , 7 ]. Infected individuals reported nausea, vomiting, and abdominal discomfort[ 6 , 8 , 9 ]. Current evidence has proposed pneumonia as a severe COVID-19 feature[ 10 ].…”

Section: Introductionmentioning

confidence: 99%

Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection

Wongtanasarasin¹

2022

World J Virol

View full text Add to dashboard Cite

The 2019 coronavirus disease (COVID-19), resulting from the severe acute respiratory syndrome 2 virus, has transformed our globe and provided a new perspective on respiratory tract infections. However, COVID-19 would not be recognized as a condition restricted to only pneumonia. This narrative review was conducted by searching manuscripts in several databases, including PubMed/ MEDLINE, Web of Science, and Reference Citation Analysis, from December 2019 to July 2022. Many studies have revealed a broad spectrum of potential systemic symptoms, including biliary complications. Although biliary injury has been observed in a very low proportion of COVID-19 patients, it is associated with increased mortalities and long-term morbidities. We identify a cholangiopathy condition in individuals during infection and after recovering from severe COVID-19, defined by a significant increase in serum alkaline phosphatase and signs of bile duct injury. Understanding the pathogeneses behind this condition would help us develop new techniques to prevent these complications. This review thoroughly discusses and summarizes the current information regarding COVID-19-associated cholangiopathy. In addition, the possible explanations for COVID-19-associated cholangiopathy are presented. Since the exact pathogenesis may not be concluded, this review could provide relevant information to encourage additional investigations shortly.

show abstract

Gastrointestinal Manifestations of Coronavirus Disease 2019 Across the United States: A Multicenter Cohort Study

Cited by 7 publications

References 21 publications

Developing a Simple Score for Diagnosis of Acute Cholecystitis at the Emergency Department

Developing a Simple Score for Diagnosis of Acute Cholecystitis at the Emergency Department

Prevalence of Different Gastrointestinal Manifestations in Patients with Covid 19 Presenting to Gastroenterology OPD at Rawal Institute of Health Sciences, Islamabad

Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection

Contact Info

Product

Resources

About